The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Dr. Rimas Lukas on the Future of Checkpoint Inhibitors in Recurrent Glioblastoma

Rimas Lukas, MD
Published Online: 5:52 PM, Fri November 20, 2015


Rimas Lukas, MD, director, Medical Neuro-Oncology, co-director, Neurology Medical Student Clerkship Program, The University of Chicago Medical Center, on PD-L1 blockade treatment and its potential in patients with recurrent glioblastoma (GBM). Lukas says the treatment has shown tolerability in patients, which allows oncologists flexibility when choosing what to combine it with.


He adds that sorting out a clear biomarker for response for these checkpoint inhibitors will be of value and could potentially change the way oncologists treat patients with recurrent GBM. 

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.